Aethlon Medical, Inc. (AEMD)
Chart Events
Performance Outlook
| Previous Close | 0.9900 |
| Open | 1.0100 |
| Bid | 1.0000 x 1200 |
| Ask | 1.0200 x 1000 |
| Day's Range | 0.9903 - 1.0100 |
| 52 Week Range | 0.8800 - 6.2200 |
| Volume | |
| Avg. Volume | 552,120 |
| Market Cap | 15.989M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6110 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AEMD
Related Research
- Aethlon Medical, Inc.DVA: What does Argus have to say about DVA?DAVITA INC has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat8 days agoArgus Research
- Zacks Small Cap Research
AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkeypox
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expanding the Potential Indications for Hemopurifier Treatment Aethlon Medical’s (NASDAQ:AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro
- PR Newswire
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2022 and provided an update on recent developments.
- PR Newswire
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.
